Nadja M. Meindl-Beinker

Learn More
Hepatocellular carcinoma (HCC) is a major public health problem due to increased incidence, late diagnosis and limited treatment options. TGF-β is known to provide cytostatic signals during early stages of liver damage and regeneration, but exerts tumor promoting effects in onset and progression of liver cancer. To understand the mechanistic background of(More)
This type of testing allows the sensitive identification of compounds that interfere with developmental processes (Balmer et al. 2014). In contrast, the use of stem cell-derived mature cells, e.g., hepatocytes or neurons for evaluation of organ toxicity , still faces major challenges (Hammad et al. 2014a; Godoy et al. 2013; Hewitt et al. 2007). It has(More)
TGF-β signaling in liver cells has variant roles in the dynamics of liver diseases, including hepatocellular carcinoma (HCC). We previously found a correlation of high levels of the important endogenous negative TGF-β signaling regulator SMAD7 with better clinical outcome in HCC patients. However, the underlying tumor-suppressive molecular mechanisms are(More)
TGF-β1 is a major player in chronic liver diseases promoting fibrogenesis and tumorigenesis through various mechanisms. The expression and function of TGF-β2 have not been investigated thoroughly in liver disease to date. In this paper, we provide evidence that TGF-β2 expression correlates with fibrogenesis and liver cancer development.Using quantitative(More)
  • 1